Break it Down: Tryptamine Therapeutics’ moves closer to IV-infused psilocybin treatment

Link copied to
clipboard

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.

In this episode, host Sarah Hughan tells all on Tryptamine Therapeutics (ASX:TYP) latest development for its psychedelic therapy drug after having it deemed safe and well-tolerated in a human study.

Psilocybin and psilocin, naturally occurring compounds found in certain mushrooms, are being studied for their therapeutic potential to modulate serotonin receptors in the brain, leading to altered perception, mood, and cognition.

Tune in to get the latest.

While Tryptamine Therapeutics is a Stockhead advertiser, it did not sponsor this content.

share

• 
• 
• 
• 

Link copied to
clipboard

SUBSCRIBE

Get the latest Stockhead news delivered free to your inbox.

Name*

Email*

This field is hidden when viewing the form

Email Lists

Morning Update

Lunch Update

Market Close Update

Weekend Update

Spotlight

Name

This field is for validation purposes and should be left unchanged.

It's free. Unsubscribe whenever you want.

By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.

You might be interested in

Break It Down

Break it Down: Cash in the bag for Tryptamine Therapeutics

October 30, 2024 | Stockhead TV

Stockhead TV

Tony’s Takeaway: Psychedelic stocks

October 21, 2024 | Tony Locantro

Long Shortz

Long Shortz with Tryptamine Therapeutics: Fantastic fibromyalgia results off the back of US psychedelic trial

August 14, 2024 | Stockhead TV